Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 - BioSpace - 世界杯赔率

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts**—**including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. * Rapid Oral LBA73: Evaluating ctDNA-guided treatment intensification in untreated advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) to identify patients who may benefit from intensified first-line therapy in the PACE-LUNG study—a multicenter, Phase II trial of additional chemotherapy for patients with persistent EGFR-mutant ctDNA in plasma at Week 3 after starting first-line osimertinib. Friday, October 23, 2026, Session: 3:15-4 p.m.